CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.

Item
http://www.wikidata.org/entity/Q37400577
A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancerAB0 blood group and prognosis in patients with pancreatic cancer.CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution.Metastatic pancreatic cancer: are we making progress in treatment?ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma.Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom ScorePrognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based ChemotherapyIncreased expression of αTubulin is associated with poor prognosis in patients with pancreatic cancer after surgical resection.Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis.Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review.Receptor tyrosine kinase inhibitors: Are they real tumor killers?The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancer.CA19-9-related tumor kinetics after first-line chemotherapy of patients with advanced pancreatic cancer: a monoinstitutional experience.
P2860

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.

Item
http://www.wikidata.org/entity/Q37400577
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CA 19-9 as a biomarker in adva ...... axitinib or gemcitabine alone.
@en
CA 19-9 as a biomarker in adva ...... axitinib or gemcitabine alone.
@nl
type
label
CA 19-9 as a biomarker in adva ...... axitinib or gemcitabine alone.
@en
CA 19-9 as a biomarker in adva ...... axitinib or gemcitabine alone.
@nl
prefLabel
CA 19-9 as a biomarker in adva ...... axitinib or gemcitabine alone.
@en
CA 19-9 as a biomarker in adva ...... axitinib or gemcitabine alone.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
CA 19-9 as a biomarker in adva ...... axitinib or gemcitabine alone.
@en
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P577
P5875
P6179
P698
P921
P932